Bruker Cash Flow Statement
NASDAQ: BRKRIndustrialsBiotechnology: Laboratory Analytical InstrumentsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Bruker free cash flow
In fiscal 2025, Bruker generated $134.1 million of operating cash flow and spent $90.8 million on capital expenditures. That left free cash flow of $43.3 million, a free-cash-flow margin of 1.3% of revenue. Free cash flow was down 68.2% from the prior year's $136.0 million.
Bruker returned $32.8 million to shareholders: $22.8 million in dividends and $10.0 million in share repurchases, equal to 76% of free cash flow. Free cash flow covered dividend payments 1.9 times.
Summary generated from market data by MetaCap's automated system. Methodology
Bruker cash flow statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 | FY 20172017-12-31 | FY 20162016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -8.30M | 113.80M | 428.50M | 298.50M | 280.60M | 161.40M | 198.00M | 181.00M | 80.30M | 154.50M |
| Net Income growth (YoY) | -107.29% | -73.44% | +43.55% | +6.38% | +73.85% | -18.48% | +9.39% | +125.40% | -48.03% | +47.28% |
| Depreciation & Amortization | 220.30M | 183.80M | 114.90M | 88.80M | 89.10M | 80.40M | 75.60M | 64.90M | 63.90M | 54.30M |
| Stock-Based Compensation | 20.20M | 25.30M | 30.90M | 27.70M | 17.20M | 16.00M | 9.60M | 11.30M | 11.00M | 9.40M |
| Change in Working Capital | 5.90M | -142.40M | -125.30M | -144.20M | -82.40M | -1.50M | -45.10M | -57.50M | -24.40M | -66.30M |
| Operating Cash Flow | 134.10M | 251.30M | 350.10M | 274.40M | 282.40M | 332.20M | 213.40M | 239.70M | 154.40M | 130.80M |
| Capital Expenditures | -90.80M | -115.30M | -106.90M | -129.20M | -92.00M | -97.20M | -73.00M | -49.20M | -43.70M | -37.10M |
| Investing Cash Flow | -196.50M | -1.76B | -326.00M | -251.60M | -192.40M | -192.70M | -158.40M | -123.40M | -30.20M | -21.80M |
| Dividends Paid | -22.80M | -30.20M | -29.40M | -29.80M | -24.20M | -24.60M | -25.00M | -25.10M | -25.40M | -25.80M |
| Share Repurchases | -10.00M | 0 | -152.30M | -263.10M | -153.30M | -123.20M | -142.30M | — | -152.20M | -160.00M |
| Debt Issued | 3.50M | 973.70M | 2.00M | 300.00K | 492.80M | 0 | 597.90M | — | — | — |
| Debt Repaid | -466.50M | -135.40M | -23.50M | -111.00M | -800.00K | — | -15.00M | — | — | -100.00K |
| Financing Cash Flow | 135.10M | 1.23B | -193.40M | -415.30M | 318.70M | -161.60M | 300.00M | -112.40M | -159.00M | -27.90M |
| Net Change in Cash | 116.40M | -304.90M | -157.10M | -423.00M | 386.20M | 3.60M | 355.60M | -2.60M | -17.00M | 74.70M |
| Free Cash Flow | 43.30M | 136.00M | 243.20M | 145.20M | 190.40M | 235.00M | 140.40M | 190.50M | 110.70M | 93.70M |
This table shows 10 annual periods of Bruker's cash flow statement, from FY 2025 back to FY 2016, across 14 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow BRKR's reporting calendar. What is a cash flow statement?